Phase I study of peptide vaccination for patients with unresectable pancreatic cancer

Phase I study of peptide vaccination for patients with unresectable pancreatic cancer - Phase I study of peptide vaccination for patients with unresectable pancreatic cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004337

Enrollment

Registered

2010-10-06

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Patients will be vaccinated once a week for 12 weeks of a treatment cycle. On each vaccination day, VEGFR1, VEGFR2, KIF20A, CDCA1 peptide(1mg) mixed with Montanide ISA-51 will be administered by subc

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.HLA-A*2402 positive patients with clinically or pathologically diagnosed unresectable pancreatic cancer. 2.Age between 20 to 80 3.No severe organ function impairment 4.Written informed consent of the patient 5.Performance Status 0-2

Exclusion criteria

Exclusion criteria: 1.Pregnancy or lactation 2.Decision of unsuitableness by principal investigator 3.Patient with severe underlying disease 4.Patient with severe allergy disease

Design outcomes

Primary

Measure	Time frame
Assessment of Safety	—

Secondary

Measure	Time frame
Assessment of clinical responses	—

Countries

Japan

Contacts

Public ContactRyuji Okuyama

Tokyo Women's Medical University Department of Gastroenterological Surgery

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026